2014 Quality Performance Results Table:
Measure Number | Measure Number | � | |||||
ACO Performance Rate | Mean performance rate (SSP- ACOs) | ||||||
ACO-1 | Getting Timely Care, Appointments, and Information | 84.32 | 80.13 | ||||
ACO-2 | How Well Your Doctors Communicate | 93.78 | 92.39 | ||||
ACO-3 | Patients’ Rating of Doctor | 93.73 | 91.58 | ||||
ACO-4 | Access to Specialists | 82.47 | 83.97 | ||||
ACO-5 | Health Promotion and Education | 54.85 | 58.29 | ||||
ACO-6 | Shared Decision Making | 76.74 | 74.6 | ||||
ACO-7 | Health Status/Functional Status | 71.79 | 71.1 | ||||
ACO-8 | Risk Standardized, All Condition Readmissions | 14.89 | 15.15 | ||||
ACO-9 | ASC Admissions: COPD or Asthma in Older Adults | 1.83 | 1.08 | ||||
ACO-10 | ASC Admission: HF | 1.32 | 1.19 | ||||
ACO-11 | Percent of Primary Care Providers Who Successfully Attested for the EHR Incentive Program Incentive Payment | 61.59 | 76.71 | ||||
ACO-12 | Medication Reconciliation | 96.26 | 82.61 | ||||
ACO-13 | Falls: Screening for Fall Risk | 47.20 | 45.6 | ||||
ACO-14 | Influenza Immunization | 31.63 | 57.51 | ||||
ACO-15 | Pneumococcal Vaccination | 47.45 | 55.03 | ||||
ACO-16 | Adult Weight Screening and Follow-up | 40.88 | 66.75 | ||||
ACO-17 | Tobacco Use Assessment and Cessation Intervention | 67.40 | 86.79 | ||||
ACO-18 | Depression Screening | 4.68 | 39.27 | ||||
ACO-19 | Colorectal Cancer Screening | 10.22 | 56.14 | ||||
ACO-20 | Mammography Screening | 19.71 | 61.41 | ||||
ACO-21 | Proportion of Adults who had blood pressure screened in past 2 years | 25.00 | 60.24 | ||||
ACO-22 | Hemoglobin A1c Control (HbA1c) ( | 67.49 | N/A | ||||
ACO-23 | Low Density Lipoprotein (LDL) ( | N/A | N/A | ||||
ACO-24 | Blood Pressure (BP) | 62.32 | N/A | ||||
ACO-25 | Tobacco Non-Use | 73.40 | N/A | ||||
ACO-26 | Aspirin Use | 72.16 | N/A | ||||
ACO-27 | Percent of beneficiaries with diabetes whose HbA1c in poor control (>9 percent) | 24.57 | 20.35 | ||||
ACO-28 | Percent of beneficiaries with hypertension whose BP | 61.80 | 68.02 | ||||
ACO-29 | Percent of beneficiaries with IVD with complete lipid profile and LDL control | N/A | N/A | ||||
ACO-30 | Percent of beneficiaries who use Aspirin or other antithrombotic | 79.26 | 80.79 | ||||
ACO-31 | Beta-Blocker Therapy for LVSD | 88.89 | 82.71 | ||||
ACO-32 | Drug Therapy for Lowering LDL-Cholesterol | N/A | N/A | ||||
ACO-33 | (ACE) Inhibitor or (ARB) Therapy for Patients with CAD and Diabetes and/or (LVSD) | 67.90 | N/A |